Roy Herbst
Overview
Explore the profile of Roy Herbst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nilsson M, Giri U, Gudikote J, Tang X, Lu W, Tran H, et al.
Clin Cancer Res
. 2015 Nov;
22(8):1940-50.
PMID: 26578684
Purpose: VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non-small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved...
12.
McLaughlin J, Han G, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al.
JAMA Oncol
. 2015 Nov;
2(1):46-54.
PMID: 26562159
Importance: Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable clinical responses in patients with non-small-cell...
13.
Warren G, Marshall J, Cummings K, Toll B, Gritz E, Hutson A, et al.
J Oncol Pract
. 2013 Aug;
9(5):258-62.
PMID: 23943904
Purpose: Assessing tobacco use and providing cessation support is recommended by the American Society for Clinical Oncology (ASCO). The purpose of this study was to evaluate practice patterns and perceptions...
14.
Tsao A, Liu S, Lee J, Alden C, Blumenschein Jr G, Herbst R, et al.
J Thorac Oncol
. 2013 Apr;
8(5):658-61.
PMID: 23584298
Background: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non-small-cell lung cancer (NSCLC) patients into four...
15.
Warren G, Marshall J, Cummings K, Toll B, Gritz E, Hutson A, et al.
J Thorac Oncol
. 2013 Mar;
8(5):543-8.
PMID: 23529191
Introduction: Tobacco use is associated with poor outcomes in cancer patients, but there is little information from oncology providers on their practice patterns or perceptions regarding tobacco use and smoking...
16.
Yamaguchi H, Hsu J, Chen C, Wang Y, Hsu M, Chang S, et al.
Clin Cancer Res
. 2013 Jan;
19(4):845-54.
PMID: 23344263
Purpose: Results of multiple clinical trials suggest that EGF receptor (EGFR) tyrosine kinase inhibitors (TKI) exhibit negative effects on platinum-based chemotherapy in patients with lung cancer with wild-type (WT) EGFR,...
17.
Ujhazy P, Herbst R
J Thorac Oncol
. 2012 Nov;
7(16 Suppl 5):S401-3.
PMID: 23160334
No abstract available.
18.
Tsao A, Liu S, Lee J, Alden C, Blumenschein G, Herbst R, et al.
J Thorac Oncol
. 2012 Oct;
7(11):1645-52.
PMID: 23059780
Background: Treating elderly non-small-cell lung cancer (NSCLC) patients in the salvage setting is challenging because of concerns of intolerance to therapy. Here we report outcomes (survival and toxicity) of elderly...
19.
Subbiah V, Brown R, Buryanek J, Trent J, Ashkenazi A, Herbst R, et al.
Mol Cancer Ther
. 2012 Aug;
11(11):2541-6.
PMID: 22914439
Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response...
20.
Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, et al.
Cancer Res
. 2012 Aug;
72(16):3901-5.
PMID: 22865459
A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic...